Find in Library

LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus

oleh: Bindu Murthy, Qihong Zhao, Takafumi Ide, Manoj Chiney, Huynh Yen Thanh Bach, Vineet Goti, Coburn Hobar, Urvi Aras